IQVIA Holdings Inc. $IQV Position Decreased by WASHINGTON TRUST Co

WASHINGTON TRUST Co lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 94,316 shares of the medical research company’s stock after selling 5,196 shares during the quarter. WASHINGTON TRUST Co’s holdings in IQVIA were worth $17,914,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. APG Asset Management N.V. increased its holdings in shares of IQVIA by 1.5% in the third quarter. APG Asset Management N.V. now owns 102,239 shares of the medical research company’s stock valued at $19,419,000 after buying an additional 1,500 shares in the last quarter. Meridian Wealth Advisors LLC boosted its stake in shares of IQVIA by 4.7% during the 3rd quarter. Meridian Wealth Advisors LLC now owns 17,849 shares of the medical research company’s stock worth $3,390,000 after acquiring an additional 797 shares in the last quarter. Rafferty Asset Management LLC grew its holdings in shares of IQVIA by 8.6% in the 3rd quarter. Rafferty Asset Management LLC now owns 18,868 shares of the medical research company’s stock worth $3,584,000 after acquiring an additional 1,499 shares during the last quarter. Huntington National Bank raised its position in shares of IQVIA by 7.8% during the third quarter. Huntington National Bank now owns 969 shares of the medical research company’s stock worth $184,000 after purchasing an additional 70 shares during the period. Finally, Argent Trust Co lifted its holdings in shares of IQVIA by 9.2% during the third quarter. Argent Trust Co now owns 32,414 shares of the medical research company’s stock valued at $6,157,000 after purchasing an additional 2,743 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IQV. Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Jefferies Financial Group cut their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. TD Cowen raised their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $231.80.

IQVIA Trading Up 5.0%

Shares of NYSE:IQV opened at $179.09 on Monday. The firm has a fifty day moving average of $212.19 and a two-hundred day moving average of $208.13. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The firm has a market capitalization of $30.39 billion, a P/E ratio of 22.79, a price-to-earnings-growth ratio of 1.72 and a beta of 1.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.